ATE387217T1 - Mannose-6-phosphat rezeptor vermittelter gentransfer zu muskelzellen - Google Patents
Mannose-6-phosphat rezeptor vermittelter gentransfer zu muskelzellenInfo
- Publication number
- ATE387217T1 ATE387217T1 AT03077205T AT03077205T ATE387217T1 AT E387217 T1 ATE387217 T1 AT E387217T1 AT 03077205 T AT03077205 T AT 03077205T AT 03077205 T AT03077205 T AT 03077205T AT E387217 T1 ATE387217 T1 AT E387217T1
- Authority
- AT
- Austria
- Prior art keywords
- mannose
- muscle cells
- phosphate receptor
- gene transfer
- mediated gene
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03077205A EP1495769B1 (de) | 2003-07-11 | 2003-07-11 | Mannose-6-Phosphat Rezeptor vermittelter Gentransfer zu Muskelzellen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE387217T1 true ATE387217T1 (de) | 2008-03-15 |
Family
ID=33442814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03077205T ATE387217T1 (de) | 2003-07-11 | 2003-07-11 | Mannose-6-phosphat rezeptor vermittelter gentransfer zu muskelzellen |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1495769B1 (de) |
| AT (1) | ATE387217T1 (de) |
| DE (1) | DE60319354T2 (de) |
| DK (1) | DK1495769T3 (de) |
| ES (1) | ES2302898T3 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2361325T3 (es) | 2004-06-28 | 2011-06-16 | The University Of Western Australia | Oligonucleótidos antisentido para inducir la omisión de exón y métodos de uso de los mismos. |
| GB0524987D0 (en) | 2005-12-08 | 2006-01-18 | Ge Healthcare Ltd | Novel imaging agents for fibrosis |
| WO2007123391A1 (en) | 2006-04-20 | 2007-11-01 | Academisch Ziekenhuis Leiden | Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene. |
| EP1857548A1 (de) | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Mittel und Verfahren zur Induktion von Exon-skipping |
| WO2008018795A1 (en) | 2006-08-11 | 2008-02-14 | Prosensa Technologies B.V. | Methods and means for treating dna repeat instability associated genetic disorders |
| DK2167136T3 (en) | 2007-07-12 | 2016-07-25 | Biomarin Tech Bv | Molecules for targeting compounds at different selected organs or tissues |
| EP2167135A2 (de) | 2007-07-12 | 2010-03-31 | Prosensa Technologies B.V. | Moleküle für targeting von verbindungen auf verschiedene ausgewählte organe, gewebe oder tumorzellen |
| USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
| NZ584793A (en) | 2007-10-26 | 2012-05-25 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| NZ587178A (en) | 2008-02-08 | 2011-11-25 | Prosensa Holding Bv | Methods and means for treating dna repeat instability associated genetic disorders |
| EP2119783A1 (de) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel |
| EP4174178A1 (de) | 2008-10-24 | 2023-05-03 | Sarepta Therapeutics, Inc. | Mehrere exon-skipping-zusammensetzungen für dmd |
| JP2012524540A (ja) | 2009-04-24 | 2012-10-18 | プロセンサ テクノロジーズ ビー．ブイ． | Ｄｍｄを処置するためのイノシンを含むオリゴヌクレオチド |
| JP5837486B2 (ja) * | 2009-07-03 | 2015-12-24 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | カチオン非依存性マンノース６−リン酸受容体を標的とする化合物 |
| EP3431603A1 (de) | 2009-11-12 | 2019-01-23 | The University Of Western Australia | Antisense-moleküle und verfahren zur krankheitsbehandlung damit |
| AU2010335039B2 (en) | 2009-12-24 | 2015-03-26 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Molecule for treating an inflammatory disorder |
| EP2806900B1 (de) | 2012-01-27 | 2021-12-15 | BioMarin Technologies B.V. | Rna-modulierende oligonukleotide mit verbesserten eigenschaften zur behandlung der duchenne- und becker-muskeldystrophie |
| AU2013336237A1 (en) | 2012-10-22 | 2015-06-11 | Sabag-Rfa Ltd | A system for delivering therapeutic agents into living cells and cells nuclei |
| KR102112892B1 (ko) | 2012-11-15 | 2020-05-19 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | 올리고뉴클레오티드 콘쥬게이트 |
| MY177989A (en) | 2013-01-30 | 2020-09-28 | Hoffmann La Roche | Lna oligonucleotide carbohydrate conjugates |
| WO2014118272A1 (en) | 2013-01-30 | 2014-08-07 | Santaris Pharma A/S | Antimir-122 oligonucleotide carbohydrate conjugates |
| IL280443B (en) | 2013-03-14 | 2022-07-01 | Sarepta Therapeutics Inc | Preparations that skip axon for the treatment of muscular dystrophy |
| EA201591792A1 (ru) | 2013-03-15 | 2016-02-29 | Сарепта Терапьютикс, Инк. | Улучшенные композиции для лечения мышечной дистрофии |
| ES2770667T3 (es) | 2013-06-27 | 2020-07-02 | Roche Innovation Ct Copenhagen As | Oligómeros antisentido y conjugados que se dirigen a PCSK9 |
| GB201408623D0 (en) | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
| TWI794662B (zh) | 2016-03-14 | 2023-03-01 | 瑞士商赫孚孟拉羅股份公司 | 用於降低pd-l1表現之寡核苷酸 |
| CN113474633A (zh) | 2019-02-26 | 2021-10-01 | 罗氏创新中心哥本哈根有限公司 | 寡核苷酸配制方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6172208B1 (en) * | 1992-07-06 | 2001-01-09 | Genzyme Corporation | Oligonucleotides modified with conjugate groups |
-
2003
- 2003-07-11 DK DK03077205T patent/DK1495769T3/da active
- 2003-07-11 EP EP03077205A patent/EP1495769B1/de not_active Expired - Lifetime
- 2003-07-11 AT AT03077205T patent/ATE387217T1/de not_active IP Right Cessation
- 2003-07-11 DE DE60319354T patent/DE60319354T2/de not_active Expired - Lifetime
- 2003-07-11 ES ES03077205T patent/ES2302898T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DK1495769T3 (da) | 2008-06-23 |
| ES2302898T3 (es) | 2008-08-01 |
| EP1495769A1 (de) | 2005-01-12 |
| DE60319354T2 (de) | 2009-03-26 |
| EP1495769B1 (de) | 2008-02-27 |
| DE60319354D1 (de) | 2008-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE387217T1 (de) | Mannose-6-phosphat rezeptor vermittelter gentransfer zu muskelzellen | |
| EP1191098A3 (de) | Pharmazeutische Zusammensetzung zur Behandlung von Duchenne-Muskeldystrophie | |
| EP2206781A3 (de) | Antisense-Oligonukleotide zur Induktion von Exon-Skipping sowie Verfahren zur Verwendung davon | |
| EP2596803A3 (de) | Verfahren zur Zielrichtung von spezifischen Zellpopulationen unter Verwendung von Maytansionoid-Konjugaten mit einem zellbindenden Mittel, verbundenen über einen nichtspaltbaren Linker, besagte Konjugate und Verfahren zur Herstellung der besagten Konjugate | |
| AU2003299785A8 (en) | Catalyst formulations containing group 11 metals for hydrogen generation | |
| JP2005500025A5 (de) | ||
| IL164637A0 (en) | Vaginal care compositions containing viable microorganisms | |
| NZ600183A (en) | Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means | |
| WO2007125429A3 (en) | Method for the synthesis of triazole- containing oligonucleotide derivatives | |
| GB0307803D0 (en) | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two | |
| DK1756259T3 (da) | Reaktorsystem med omrørt beholder | |
| EP1608781A4 (de) | Nichtinvasive pränatale genetische diagnose unter verwendung transzervikaler zellen | |
| ATE391134T1 (de) | Oligonukleotid n3'-p5' thiophosphoramidate: ihre synthese und verwendung | |
| IL186139A0 (en) | Epidermal growth factor receptor gene copy number | |
| EP1671998A3 (de) | Verfahren zur Herstellung von Komponenten mit Indolocarbazol-Gruppen | |
| EP1592813A4 (de) | Testverfahren für gruppenübertragungsreaktionen | |
| Lundin et al. | Increased stability and specificity through combined hybridization of peptide nucleic acid (PNA) and locked nucleic acid (LNA) to supercoiled plasmids for PNA-anchored “Bioplex” formation | |
| EP1942096A3 (de) | Aliphatisches Polyamin mit modifizierter Kette | |
| IL149599A0 (en) | Use of disease-associated gene | |
| Hu et al. | Cellular localization and allele-selective inhibition of mutant huntingtin protein by peptide nucleic acid oligomers containing the fluorescent nucleobase [bis-o-(aminoethoxy) phenyl] pyrrolocytosine | |
| WO2005072053A9 (en) | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of colon cancer | |
| EP1129725A3 (de) | Oligonukleotid-Konjugate | |
| JP2003508618A5 (de) | ||
| Sando et al. | Facile preparation of DNA-tagged carbohydrates | |
| AU2002367785A8 (en) | Allosteric nucleic acid sensor molecules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |